SENS SENS
Company Profile ↓Company Overview
SENS (SENS) is a publicly traded company listed on with a market capitalization of $213.76M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 113.7% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $35.26M (+56.9% YoY); net profit $-69.11M.
- Trailing 12 Months Year-on-year growth — revenue +56.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 113.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 113.66% |
| 1 Year: | 56.89% |
Stock Price Performance
| 1 Year: | -47.03% |
| 6 Months: | -27.35% |
| 3 Months: | +3.60% |
| 1 Month: | -2.81% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)46.37 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 113.7% over 5 years.
CONS
- Trading 54.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 553.00K | 814.00K | 2.10M | 2.91M | 2.95M | 553.00K | 837.00K | 7.19M | 1.24M | 1.48M | 959.00K | - | 31.00K | 216.00K | 514.00K | - | 487.00K | 433.00K | 276.00K | 292.00K | 137.00K | 4.62M | 4.14M | 4.13M | 6.10M | 5.05M | 4.87M | 4.26M | - | 6.26M | 6.65M | 8.10M | 14.26M | 11.71M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.75M | 3.53M | 4.63M | 6.59M | 4.77M |
| Gross Profit | - | - | - | -15.00K | -77.00K | -236.00K | -492.00K | -900.00K | -860.00K | -1.13M | -362.00K | -216.00K | -2.58M | -4.98M | -3.31M | -4.55M | -3.34M | -8.24M | -19.63M | -1.14M | 835.00K | 2.58M | 526.00K | 392.00K | -1.25M | 527.00K | 824.00K | 756.00K | 414.00K | 417.00K | 1.17M | 335.00K | 298.00K | -4.05M | - | 1.50M | 3.12M | 3.47M | 7.67M | 6.94M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.99M | 17.44M | 23.07M | 28.59M | 38.79M |
| Operating Income | -8.31M | -8.19M | -10.93M | -11.55M | -10.51M | -9.44M | -12.40M | -11.64M | -16.61M | -15.67M | -15.93M | -20.06M | -22.98M | -28.61M | -29.77M | -34.65M | -31.36M | -34.88M | -43.83M | -12.53M | -12.47M | -10.31M | -11.32M | -15.89M | -16.03M | -15.16M | -17.04M | -17.57M | -19.71M | -19.87M | -19.02M | -18.23M | -19.49M | -22.85M | - | -13.49M | -14.32M | -19.60M | -20.93M | -31.85M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -12.45M | -12.99M | -17.98M | -19.23M | -30.60M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.43M | 1.15M | 1.17M | 1.21M | 1.19M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -14.26M | -14.50M | -19.53M | -20.82M | -32.33M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -8.59M | -8.41M | -11.22M | -11.86M | -10.89M | -9.96M | -13.07M | -12.37M | -17.38M | -16.27M | -22.27M | -32.50M | -31.88M | -7.32M | -29.36M | -31.07M | -19.50M | -35.61M | -42.59M | -7.51M | -23.43M | -101.63M | -249.51M | -180.31M | 42.91M | 86.72M | 104.23M | -60.39M | 1.32M | -20.42M | -24.10M | -18.88M | -20.29M | -23.98M | - | -14.26M | -14.50M | -19.53M | -20.82M | -32.33M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.10 | - | -0.68 | -0.42 | 0.08 | -0.03 | -0.03 | -0.13 | 0.00 | -0.04 | -0.04 | -0.03 | -0.03 | -0.77 | - | -0.02 | -0.02 | -0.43 | - | -0.71 |
| R&D Expense | 4.68M | - | 6.42M | 7.54M | 6.88M | - | 7.00M | 5.60M | 9.77M | - | 8.11M | 8.29M | 7.40M | - | 7.11M | 10.50M | 11.08M | - | 7.36M | 3.80M | 4.57M | - | 5.25M | 7.11M | 7.20M | 7.80M | 9.30M | 10.98M | 12.40M | 12.83M | 12.77M | 10.44M | 10.80M | 10.55M | - | 7.30M | 7.71M | 7.76M | - | 8.61M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2014 | Jun 2015 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 38.00K | 332.00K | 529.00K | 2.04M | 4.92M | 1.37M | - | 16.39M | 22.39M | 22.47M | 35.26M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | 13.66M | 19.30M | 21.94M | 19.49M |
| Gross Profit | - | - | 38.00K | -328.00K | -3.38M | -8.15M | -19.45M | -17.37M | - | 2.73M | 3.09M | 533.00K | 15.76M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 71.35M | 78.69M | 75.38M | 84.10M |
| Operating Income | -18.70M | - | -28.81M | -42.43M | -56.31M | -87.58M | -130.66M | -79.13M | - | -68.63M | -75.60M | -74.84M | -68.34M |
| EBITDA | - | - | - | - | - | - | - | - | - | 161.81M | -48.01M | -68.70M | -62.65M |
| Interest Expense | - | - | - | - | - | - | - | - | - | 18.70M | 11.11M | 8.44M | 4.95M |
| Pretax Income | - | - | - | - | - | - | - | - | - | 142.12M | -60.39M | -78.62M | -69.11M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -18.89M | -67.59K | -29.88M | -43.93M | -59.10M | -93.97M | -115.55M | -175.17M | - | 142.12M | -60.39M | -78.62M | -69.11M |
| Diluted EPS | - | - | - | - | - | - | -0.61 | -0.77 | - | -0.11 | -0.11 | -2.50 | -1.66 |
| R&D Expense | 12.88M | - | 18.25M | 26.35M | 30.73M | 31.86M | 38.43M | 20.41M | 27.22M | 39.72M | 48.75M | 41.14M | 31.59M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2013 | Jun 2014 | Dec 2014 | Jun 2015 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 10.00K | 20.00M | 996 | 5.42M | 22.27M | 45.94M | 159.97M | 132.80M | 35.92M | - | 177.67M | 138.22M | 100.44M | 126.27M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | 161.20M | 130.03M | 91.44M | 117.53M |
| Cash & Equivalents | 8.25M | - | 18.92M | - | 3.94M | 13.05M | 16.15M | 136.79M | 95.94M | 18.00M | - | 35.79M | 75.71M | 74.60M | 40.23M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | 7.31M | 8.78M | 4.42M | 6.70M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | 2.45M | 4.53M | 6.29M | 12.12M |
| Total Liabilities | - | - | 12.08M | - | 15.12M | 27.15M | 38.68M | 88.71M | 141.45M | 177.19M | - | 180.25M | 102.42M | 116.99M | 65.22M |
| Current Liabilities | - | 2.92K | 2.04M | 46.51K | 7.33M | 11.62M | 23.14M | 28.89M | 126.71M | 16.64M | - | 31.47M | 17.26M | 38.85M | 24.35M |
| Long Term Debt | - | - | - | - | - | - | - | - | 11.80M | 57.22M | - | 56.38M | 41.20M | 34.70M | 35.59M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | 75.38M | 47.78M | 61.05M | 41.37M |
| Total Equity | 6.16M | 7.08K | 7.91M | -45.51K | -9.70M | -4.88M | 7.27M | 71.26M | -8.65M | -144.08M | - | -2.58M | 35.80M | -16.55M | 61.05M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | 479.64M | 530.36M | 595.35M | 41.27M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2015 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -10.27K | -25.46M | -38.02M | -55.74M | -90.77M | -136.05M | -67.42M | - | -66.31M | -70.16M | -60.47M | -59.13M |
| Investing Cash Flow | - | -202.00K | -7.77M | -13.23M | 19.43M | -1.04M | -181.00K | - | 26.88M | 89.71M | 32.84M | -53.42M |
| Financing Cash Flow | 4.73K | 10.68M | 54.89M | 72.07M | 191.99M | 96.24M | -10.13M | - | 41.76M | 20.37M | 26.83M | 78.19M |
| Capital Expenditure | - | - | - | - | - | - | - | - | -312.00K | -350.00K | -2.24M | -1.12M |
| Free Cash Flow | - | - | - | - | - | - | - | - | -66.62M | -70.51M | -62.70M | -60.24M |
| Net Change in Cash | - | - | - | - | - | - | - | - | 2.33M | 39.92M | -797.00K | -34.36M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2014 | Jun 2015 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | 100.0% | -98.8% | -639.9% | -399.5% | -395.0% | -1,269.4% | - | 16.6% | 13.8% | 2.4% | 44.7% |
| Operating Margin % | - | - | -75,821.1% | -12,781.0% | -10,645.2% | -4,295.1% | -2,653.6% | -5,784.4% | - | -418.7% | -337.7% | -333.0% | -193.8% |
| Net Margin % | - | - | -78,623.7% | -13,231.9% | -11,172.2% | -4,608.7% | -2,346.6% | -12,804.7% | - | 867.2% | -269.7% | -349.8% | -196.0% |
| ROE % | -238.7% | 148.5% | 308.1% | 900.8% | -813.3% | -131.9% | 1,336.0% | 121.6% | - | -5,517.0% | -168.7% | 474.9% | -113.2% |
| ROCE % | -104.2% | - | 1,506.9% | -398.6% | -246.9% | -66.8% | -2,144.5% | -410.4% | - | -46.9% | -62.5% | -121.5% | -67.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SENS
KORU Medical Systems, Inc. (KRMD) Q2 Earnings and Revenues Beat Estimates
KORU Medical Systems, Inc. (KRMD) delivered earnings and revenue surprises of +150.00% and +2.78%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?…
Omnicell (OMCL) Q2 Earnings and Revenues Top Estimates
Omnicell (OMCL) delivered earnings and revenue surprises of +95.83% and +0.83%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Senseonics Holdings, Inc. Schedules Second Quarter 2026 Earnings Release and Conference Call for August 6, 2026 at 4:30 P.M. Eastern Time
GERMANTOWN, Md., July 21, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today announced that it pl…
Global Blood Glucose Monitoring System Market Size to Reach USD 39.4 Billion by 2035 | Growing at 8.9% CAGR | Industry Trends, Market Share & Forecast – Custom Market Insights
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Blood Glucose Monitoring System Market size & share revenue was valued at approximately USD 16.8 Billion in 2…
DXCM Grew. The Stock Did Not. Someone Is Wrong
The company’s business grew at a healthy clip, yet its stock price went sideways and its valuation fell. Something has to give.
Glucotrack Clears Key Milestone to Commercialize Its Implantable CGM
By Karen Roman Glucotrack, Inc. (Nasdaq: GCTK) said the US Patent and Trademark Office issued a Notice of Allowance for a patent application which expands the intellectual property protecting the company’s continuous blood glucose monitorin…
SENS — Frequently Asked Questions
What is the current share price of SENS?
As of 2026-08-05 17:25 PDT, SENS trades at $5.18 on NASDAQ/NYSE. Its 52-week range is $4.86 to $11.30.
What is the market capitalisation of SENS?
SENS has a market capitalisation of $213.76M on NASDAQ/NYSE.
What is the P/E ratio of SENS?
SENS trades at a trailing price-to-earnings (P/E) ratio of -3.12. Its price-to-book (P/B) ratio is 3.50.
What is the return on equity (ROE) of SENS?
SENS has a return on equity (ROE) of -113.21%. Its return on capital employed (ROCE) is -67.05%.
Is SENS a good stock to buy?
This page provides a data-driven analysis of SENS, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.